CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement

Reference

• ABERNETHY, D. R., GREENBLATT, D. J., MORSE, D. S. and SHADER, R. I., 1985, Interaction of propoxyphene with diazepam, alprazolam and lorazepam. British Journal of Clinical Pharmacology, 19, 51–57.
   PubMed Web of Science ®Google Scholar
• BERTZ, R. J. and GRANNEMAN, G. R., 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210–258.
   PubMed Web of Science ®Google Scholar
• BROSEN, K., GRAM, L. F., SCHOU, J., LARSEN, N. E. and THAYSSEN, P., 1985, Dextropropoxyphene kinetics after single and repeated oral doses in man. European Journal of Clinical Pharmacology, 29, 79–84.
   PubMedGoogle Scholar
• COLLER, J. K., SomoGYI, A. A. and BOCHNER, F., 1997, Association between CYP2C19 genotype and proguanil oxidative polymorphism. British Journal of Clinical Pharmacology, 43, 659–660.
   PubMedGoogle Scholar
• DUE, S. L., SULLIVAN, H. R. and MCMAHON, R. E., 1976, Propoxyphene: pathways of metabolism in man and laboratory animals. Biomedical Mass Spectrometry, 3, 217–225.
   PubMedGoogle Scholar
• EBERT, B., ANDERSEN, S., HJEDS, H. and DICKENSON, A. H., 1998, Dextropropoxyphene acts as a noncompetitive N-methyl-D-aspartate antagonist. Journal of Pain and Symptom Management, 15, 269–274.
   PubMed Web of Science ®Google Scholar
• ELONEN, E. and NEUVONEN, P. J., 1984, Mixed dextropropoxyphene poisoning: concentration—effect relationships and effect of naloxone. International Journal of Clinical Pharmacology and Therapeutic Toxicology, 22, 16–19.
   PubMedGoogle Scholar
• FLANAGAN, R. J., JOHNSTON, A., WHITE, A. S. and CROME, P., 1989, Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage. British Journal of Clinical Pharmacology, 28, 463–469.
   PubMedGoogle Scholar
• GAILLARD, Y. and PEPIN, G., 1998, Gas chromatographic-mass spectrometric quantitation of dextropropoxyphene and nordextropropoxyphene in hair and whole blood after automated on-line solid-phase extraction application in twelve fatalities. Journal of Chromatography B, 709, 69–77.
   PubMedGoogle Scholar
• GRUBER, C. M., MILLER, C. L., FINNERAN, J. and CHERNISH, S. M., 1956, The effectiveness of dextropropoxyphene hydrochloride and codeine phosphate as determined by two methods of clinical testing for relief of chronic pain. Journal of Pharmacology and Experimental Therapeutics, 118, 280–285.
   PubMedGoogle Scholar
• HANSEN, B. S., DAM, M., BRANDT, J., HVIDBERG, E. F., ANGELO, H., CHRISTENSEN, J. M. and Lous, P., 1980, Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man. Acta Neurologica Scandinavica, 61, 357–367.
   PubMedGoogle Scholar
• HAWTON, K., SIMKIN, S. and DEEKS, J., 2003, Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings. British Medical Journal, 326, 1006-1008. HENTHORN, T. K., SPINA, E., DUMONT, E. and VON BAHR, C., 1989, In vitro inhibition of a polymorphic human liver P-450 isozyme by narcotic analgesics. Anesthesiology, 70, 339–342.
   Google Scholar
• HUTCHINSON, M. R., MENELAOU, A., FOSTER, D. J., COLLER, J. K. and SOMOGYI, A. A., 2004, CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 57, 287–297.
   PubMed Web of Science ®Google Scholar
• INABA, T., TYNDALE, R. E. and MAHON, W. A., 1986, Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. British Journal of Clinical Pharmacology, 22, 199–200.
   PubMed Web of Science ®Google Scholar
• JAMES, H. M., COLLER, J. K., GILLIS, D., BAHNISCH, J., SALLUSTIO, B. C. and SOMOGYI, A. A., 2004, A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. International Journal of Clinical Pharmacology and Therapeutics (in press).
   Google Scholar
• KERRY, N. L., Somoo,n, A. A., BOCHNER, F. and Mucus, G., 1994, The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. British Journal of Clinical Pharmacology, 38, 243–248.
   Google Scholar
• KIRKWOOD, L. C., NATION, R. L. and Somoo,n, A. A., 1997, Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. British Journal of Clinical Pharmacology, 44, 549–555.
   Google Scholar
• KRANTZ, T., THISTED, B., STROM, J., ANGELO, H. R. and SORENSEN, M. B., 1986, Severe acute propoxyphene overdose: plasma concentrations of propoxyphene and norpropoxy-phene and the effect of dopamine on circulatory failure. Acta Anaesthesiologica Scandinavica, 30, 271–276.
   PubMed Web of Science ®Google Scholar
• LOWRY, 0. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   Google Scholar
• MILLER, J. A., ROBBINS, E. B. and MEYERS, D. B., 1963, Antitussive activity of a series of dialkylaminodiphenylbutanol esters. Journal of Pharmaceutical Sciences, 52, 446–451.
   Google Scholar
• MILLER, R. R., FEINGOLD, A. and PAXINOS, J., 1970, Propoxyphene hydrochloride. A critical review. Journal of the American Medical Association, 213, 996–1006.
   PubMed Web of Science ®Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• NICKANDER, R. C., EMMERSON, J. L., HYNES, M. D., STEINBERG, M. I. and SULLIVAN, H. R., 1984, Pharmacologic and toxic effects in animals of dextropropoxyphene and its major metabolite norpropoxyphene: a review. Human Toxicology, 3 (Suppl.), 13S–36S.
   Google Scholar
• NICKANDER, R., SMITS, S. E. and STEINBERG, M. I., 1977, Propoxyphene and norpropoxyphene: pharmacologic and toxic effects in animals. Journal of Pharmacology and Experimental Therapeutics, 200, 245–253.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. II. Solubilisation, purification and properties. Journal of Biological Chemistry, 234, 2374–2385. PEARSON, R. M., 1984, Pharmacokinetics of propoxyphene. Human Toxicology, 3 (Suppl.), 37S–40S.
   Google Scholar
• PETTERSSON, K. J. and NILSSON, L. B., 1992, Determination of dextropropoxyphene and norpropoxyphene in plasma by high-performance liquid chromatography. Journal of Chromatography, 581, 161–164.
   PubMedGoogle Scholar
• ROBSON, R. A., MINERS, J. 0., WHITEHEAD, A. G. and BIRKETT, D. J., 1987, Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition. British Journal of Clinical Pharmacology, 23, 772–775.
   Google Scholar
• SANZ, E. J. and BERTILSSON, L., 1990, d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo. Therapeutic Drug Monitoring, 12, 297–299.
   PubMedGoogle Scholar
• SHIRAN, M. R., CHOWDRY, J., ROSTAMI-HODJEGAN, A., ELLIS, S. W., LENNARD, M. S., IQBAL, M. Z., LAGUNDOYE, 0., SEIVEWRIGHT, N. and TUCKER, G. T., 2003, A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. British Journal of Clinical Pharmacology, 56, 220–224.
   Google Scholar
• SPINA, E., PISANI, F. and PERUCCA, E., 1996, Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clinical Pharmacokinetics, 31, 198–214.
   PubMed Web of Science ®Google Scholar
• WETLI, C. V. and BEDNARCZYK, L. R., 1980, Deaths related to propoxyphene overdose: a ten-year assessment. Southern Medical Journal, 73, 1205–1209.
   PubMed Web of Science ®Google Scholar
• YOUNG, R. J., 1983, Dextropropoxyphene overdosage. Pharmacological considerations and clinical management. Drugs, 26, 70–79.
   PubMed Web of Science ®Google Scholar
• ZANGER, U. M., VILBois, F., HARDWICK, J. P. and MEYER, U. A., 1988, Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry, 27, 5447–5454.
   PubMed Web of Science ®Google Scholar